Question
The first approved treatment for primary progressive multiple sclerosis, ocrelizumab, targets this antigen. For 10 points each:
[10m] Name this antigen found on the surface of B cells. This antigen is targeted by the first antibody approved for cancer patients, rituximab.
ANSWER: CD20 [accept MS4A1]
[10h] In addition to attracting NK cells in antibody-dependent cellular cytotoxicity, rituximab also induces complement-dependent cytotoxicity. This protein complex binds to antibody-antigen complexes in the classical complement pathway.
ANSWER: C1 [or complement component 1; accept C1q or complement component 1q]
[10e] The suffix “-mab” in rituximab and ocrelizumab refers to them being medicines composed of these antibodies. Fused hybridomas produce these antibodies which target a single epitope.
ANSWER: monoclonal antibodies [or mAb]
<Science - Biology>
Summary
| 2024 ARGOS @ Chicago | 11/23/2024 | Y | 6 | 13.33 | 100% | 33% | 0% |
| 2024 ARGOS @ Columbia | 11/23/2024 | Y | 3 | 3.33 | 33% | 0% | 0% |
| 2024 ARGOS @ McMaster | 11/17/2024 | Y | 5 | 8.00 | 60% | 20% | 0% |
Data
| NJ TRANSit (and anwen i guess) | 12 Litres of Green Tea | 0 | 0 | 0 | 0 |
| Walston et. al. | jeff mcneil #1 morningside heights fan club | 0 | 0 | 0 | 0 |
| Cope is the thing with feathers | just one more half-dot bro | 0 | 0 | 10 | 10 |